AbbVie’s Venclexta update puts long-term CLL treatment-free survival back in focus
Find out how AbbVie’s nine-year venetoclax CLL data could reshape fixed-duration treatment decisions and long-term leukemia care.
Can Oryzon Genomics, S.A. turn iadademstat into a platform therapy for acute myeloid leukemia?
Can Oryzon Genomics turn iadademstat into a scalable AML platform therapy? Explore the EHA 2026 clinical and commercial implications.
Ficlatuzumab joins Beat AML trial: is AVEO’s c-Met inhibitor ready for broader testing?
AVEO begins new trial of ficlatuzumab in front-line AML with Beat AML. Find out what this signals for older patients and c-Met inhibitor development.